Financial Performance - Total GAAP costs and expenses for Q4 2023 were $12.5 million, up from $8.7 million in Q4 2022, primarily due to a $3.3 million increase in non-cash stock-based compensation[5] - GAAP net loss for Q4 2023 was ($11.9) million compared to ($9.2) million in Q4 2022, while non-GAAP net loss was ($8.3) million compared to ($8.1) million in the prior year[6] - For the full year 2023, total GAAP costs and expenses were $43.6 million, a decrease from $58.8 million in 2022, with non-GAAP costs and expenses at $35.1 million compared to $51.3 million in 2022[7] - Full year GAAP net loss for 2023 was ($42.2) million, improved from ($58.5) million in 2022, while non-GAAP net loss was ($33.8) million compared to ($51.1) million in the previous year[9] - Total revenues for the three-month period ended December 31, 2023, were $0, a decrease of 9% compared to $700,000 in the same period of 2022[25] - The net loss for the three-month period ended December 31, 2023, was $11,933,000, compared to a net loss of $9,197,000 for the same period in 2022, reflecting a 30% increase in losses[25] - The company reported a comprehensive loss of $11,933,000 for the three-month period ended December 31, 2023, compared to a comprehensive loss of $9,197,000 in the same period of 2022[25] - Basic and diluted net loss per share for the three-month period ended December 31, 2023, was $0.22, compared to $0.25 for the same period in 2022[25] - Non-GAAP net loss for the three-month period ended December 31, 2023, was $8,285,000, compared to $8,113,000 for the same period in 2022[30] - Total cost and expenses for the three-month period ended December 31, 2023, were $12,533,000, compared to $8,736,000 in the same period of 2022, marking a 43% increase[25] Cash Position - Cash and cash equivalents as of December 31, 2023, totaled $44.4 million, down from $61.1 million a year earlier, with cash used in Q4 2023 at $6.9 million compared to $8.0 million in Q4 2022[10] Research and Development - Research and development expenses increased to $7,799,000 for the three-month period ended December 31, 2023, up from $4,095,000 in the same period of 2022, representing a 90% increase[25] - The company is actively developing its CellFX nsPFA technology for treating atrial fibrillation and other conditions, with positive early clinical results reported[19] Regulatory and Strategic Initiatives - The company received FDA 510(k) clearance for the CellFX nsPFA Percutaneous Electrode System and completed enrollment in a 30-patient clinical trial for benign thyroid nodules[8] - The company plans to initiate a rights offering pending SEC approval, allowing it to sell up to $50 million worth of securities over three years[8] - The company aims to optimize resources and streamline operations to advance the development of its product portfolio[7] Cost Structure Changes - Total stock-based compensation expense for the twelve-month period ended December 31, 2023, was $7,181,000, an increase from $5,191,000 in 2022[25] - The company reclassified certain expenses due to a shift in focus from dermatology to cardiology, impacting the cost structure[25] - Non-GAAP financial measures are used to provide a clearer view of ongoing operations, excluding stock-based compensation, depreciation, and restructuring charges[15]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (State or ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 ...

Pulse Biosciences Inc. (NASDAQ:PLSE) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (Stat ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (Sta ...

For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-5696597 (State or ...

Pulse Biosciences Inc. (NASDAQ:PLSE) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Trip Taylor – Investor Relations Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions James Hollingsworth – Private Investor Operator Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences’ Fourth Quarter 2022 Earnings Conference Cal ...